Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study-Reference-Cited by-同舟云学术

Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study

Published:2015-05-13 Issue:6 Volume:20 Page:1063-1071
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Osawa Masahiro,Kudoh Shoji,Sakai Fumikazu,Endo Masahiro,Hamaguchi Tetsuya,Ogino Yumiko,Yoneoka Miyo,Sakaguchi Motonobu,Nishimoto Hiroyuki,Gemma Akihiko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-015-0834-3.pdf

Reference28 articles.

1. Yang XD, Jia XC, Corvalan JR et al (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17–23

2. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

3. Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980–988

4. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

5. Weiner LM, Belldegrun AS, Crawford J et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502–508

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The radiologist’s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review;Insights into Imaging;2024-08-01

2. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum;Expert Review of Respiratory Medicine;2024-02

3. Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases;Respiratory Research;2024-01-14

4. Anti-EGFR Antibodies (Cetuximab, Panitumumab, and Necitumumab);Analysis File of Drug-Induced Lung Injury;2024

5. Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective;Current Oncology;2023-08-30